Federal award (DELIVERY ORDER, fiscal year 2021)
Recipient: THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2019-09-15 to 2023-03-14
Current total value of award: $912585
Description: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS  TASK ORDER TITLE: REPURPOSING OF MACROLIDE ANTIBIOTIC CLARITHROMYCIN FOR THE PREVENTION OF LUNG AND BREAST CANCER